Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


MedImmune Appoints Development Leadership Team

This article was originally published in The Pink Sheet Daily

Executive Summary

Former Cambridge Antibody Technology exec to oversee product development.

You may also be interested in...

AstraZeneca Concentrates Biologics At MedImmune, Ups R&D

MedImmune, which absorbs Cambridge Antibody Technologies, will continue to operate independently from AstraZeneca.

AstraZeneca Hears CAT’s Meow With Biotech Acquisition

Deal for Cambridge Antibody Technology, valued at $1.07 bil., will shift focus of AstraZeneca’s pipeline.

A Tecfidera Comeback? Investors Await More On Patent Plans From Biogen

Biogen has been granted new US patents for Tecfidera after generics already launched. It's unclear how Biogen will proceed but management could shed more light on the matter during the first quarter call.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts